Growing Prevalence of Behavioral Disorders
According to the U.S. Department of Health and Human Services (DHHS), it is estimated that one in every five (20%) children and adolescents has a mental health disorder at some point in their life from childhood to adolescence. At least, one in 10, or about 6 million people have a serious emotional disturbance at some point in their life. Estimating the prevalence of behavioral rehabilitation disorders in children is critical, as it helps in providing mental health treatments they need. Several internet interventions have been developed for the treatment of common mental disorders. They help in remote monitoring of the patient, and thus are easily accessible by them. Also, these online counseling sessions are cost-effective.
Additionally, increasing availability of therapies for behavioral rehabilitation, increasing preferences of partial hospitalization programs (PHP) and rising government initiatives for behavioral disorders helps in the growth of the market.
Lack of Awareness of Behavioral Disorders
According to Mental Health America, 26.2% of the American population is suffering from a diagnosable mental health or addiction disorder, which is equal to 59 million Americans. However, 52% of Americans are not seeking any help for mental problems. This lack of proper awareness of behavioral disorder is restraining the growth of behavioral rehabilitation market. Many people with serious behavioral rehabilitation are facing challenges such as the struggle with the symptoms disorders, and on the other hand, they are challenged by stereotypes and prejudice that are a result of misconceptions about these behavioral disorders. Thus, the impact of stigma on people with behavioral disorders is restraining the behavioral rehabilitation market.
Additionally, lack of proper reimbursement is also restraining the growth of behavioral rehabilitation market, globally.
North America is Dominating the Market
North America is dominating behavioral rehabilitation market as rising incidences of mental disorders and availability of treatment, which are driving factors responsible for the high market share. Also, government initiatives are driving the growth of the market. The Affordable Care Act categorizes behavioral disorders as essential healthcare, which helps in covering major parts of the treatment.
Key Developments in the Market
- December 2017: Universal Health Services Inc. announces the acquisition of Memorial Behavioral Health (MBH), which provides health facility for adults, adolescents and children.
Reasons to Purchase this Report
- Current and future behavioral rehabilitation market outlook in the developed and emerging markets
- Analyzing various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares and strategies employed by the major market players
- 3 months analyst support along with the Market Estimate sheet (in excel)
This report can be customized to meet your requirements.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product & Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Growing Capital Investment from Key Market Players
6.1.2 Rise in the Prevalence of Chronic Diseases
6.1.3 Loss of Patent Exclusivity of the Leading Biologics Drugs
6.1.4 Growing Demand and Higher Acceptability for Innovative Therapies
6.2 Market Restraints
6.2.1 Stringent Regulatory Process and Initial High Capital Investment
6.2.2 Rising Control and Cost for Accessing Biologics
6.4 Key Challenges
7. Market Segmentation
7.1 By Product
7.1.1 Monoclonal Antibodies
7.1.3 Recombinant Hormones/Proteins
7.1.4 Cell Therapy
7.1.5 Gene Therapy
7.2 By Application
7.2.2 Infectious Diseases
7.2.3 Rare Diseases
7.2.4 Autoimmune Diseases
7.3 By Geography
7.3.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 Australia & New Zealand
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
7.3.4 Middle East & Africa
220.127.116.11 South Africa
18.104.22.168 Rest of the Middle East & Africa
7.3.5 South America
22.214.171.124 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbvie Inc.
9.3 Eli Lilly and Company
9.4 F. Hoffmann-La Roche Ltd
9.5 Glaxosmithkline Plc.
9.6 Johnson & Johnson
9.7 Merck & Co
9.8 Novo Nordisk
9.9 Pfizer Inc.
10. Future of the Market
- Acadia Healthcare
- Universal Health Services Inc.
- Magellan Health Inc.
- Psychiatric Solutions Inc.
- Crc Health
- Aurora Behavioral Health System
- Behavioral Health Group
- Haven Behavioral Healthcare Inc.
- Springstone Inc.
- American Addiction Centers Inc